Our website uses cookies to improve your on-site experience. By using the website, cookies are being used as described in our Policy Document
Warning: To log in you will need to enable cookies and reload the page (Policy Document)
My ePortfolio Register   

European Lung Cancer Congress 2019 /
ALK-positive NSCLC: Current landscape

10th - 13th Apr 2019

Please rate this video

Please complete at least one question.

  1. The information in this video was of interest to me Disagree Agree
  2. The information in this video is likely to improve my clinical practice or research Disagree Agree
  3. I would recommend this video to my colleagues Disagree Agree
Thanks for rating
There has been a problem, please refresh and try again.
Published: 29.04.19
Views: 2821

Dr Antonio Passaro and Prof Rafal Dziadziuszko

Dr Antonio Passaro chairs a discussion with Prof Rafal Dziadziuszko on the current landscape and latest developments in ALK-positive non-small-cell lung cancer (NSCLC).

In this video, Prof Dziadziuszko outlines the current guidelines for patients with ALK-positive NSCLC; in which first-line treatments should involve the use of ALK inhibitors - as these have demonstrated improved progression-free survival (PFS) and quality of life compared to using traditional chemotherapy.

He also describes the historic use of fluorescent in-situ hybridisation (FISH) to identify ALK-positive translocations; however, due to its inefficiency, immunohistochemistry and next-generation sequencing are now the preferred methods of diagnosis.

For the first-line setting, Prof Dziadziuszko emphasises the importance of considering the toxicity and efficacy profiles of each inhibitor (both within the brain and in systemic regions) for the treatment of ALK-positive NSCLC.

He also anticipates that the next generation ALK inhibitors (such as alectinib, brigatinib, lorlatinib and ensartinib) will improve patient outcomes.

For the second-line setting, the use of stereotactic radiation combined with the continued use of the original ALK inhibitor used in the first-line setting should be considered for these patients. However, there have been encouraging data that support the use of third-generation ALK inhibitors (e.g. brigatinib or lorlatinib) for patients who fail the standard-of-care drug, crizotinib.

Prof Dziadziuszko describes the success of alectinib by improving PFS; as well as decreasing CNS progression during the phase III ALEX trial.

Prof Dziadziuszko concludes the discussion by highlighting the importance of evaluating CNS progression and toxicity when using ALK inhibitors -stating that the toxicity profile of alectinib is favourable.

New developments and guidelines about ALK-positive NSCLC
ALK-positive NSCLC treatment options in the first-line setting
ALK-positive NSCLC treatment options in the second-line setting
Highlights from the ALEX clinical trial study


This programme has been supported by Roche.

Previous conferences: highlights

Founding partners

European Cancer Organisation European Institute of Oncology

Founding Charities

Foundazione Umberto Veronesi Fondazione IEO Swiss Bridge

Published by

ecancer Global Foundation